{"disease":{"id":"ovarian-neoplasms","name":"Ovarian Neoplasms","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":7},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-07260437","indication_name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07260437","generic_name":"pf-07260437","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Unknown","drug_class":"Unknown oncology compound","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development."},{"drug_id":"felmetatug-vedotin","indication_name":"Ovarian Neoplasms","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Felmetatug Vedotin","generic_name":"felmetatug-vedotin","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Given into the vein (IV; intravenously)","quality_score":null,"revenue":null,"mechanism":"Given into the vein (IV; intravenously)"}],"offLabel":[],"totalMarketed":0,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT06528236","title":"Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT00341458","title":"Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics","phase":"","overall_status":"COMPLETED","enrollment_count":6086,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03291262","title":"Survival Outcomes of Ovarian Malignancies in Chinese Population","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT06223763","title":"SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT03602859","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT03740165","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1367,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01015118","title":"LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1366,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03038100","title":"A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1301,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07035587","title":"Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04188652","title":"Diagnosing Ovarian Cysts - the DOC Study","phase":"","overall_status":"COMPLETED","enrollment_count":1123,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06564428","title":"A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT04460768","title":"An INternational Frontline Ovarian Cancer Real World Management Study","phase":"","overall_status":"COMPLETED","enrollment_count":989,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03994653","title":"Cancer Loyalty Card Study","phase":"","overall_status":"COMPLETED","enrollment_count":963,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07318558","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02655016","title":"A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT03193671","title":"Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis","phase":"","overall_status":"COMPLETED","enrollment_count":684,"lead_sponsor_name":"Göteborg University","has_results":false},{"nct_id":"NCT04589039","title":"A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":662,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05116189","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":643,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04498117","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":615,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03294343","title":"Risk-Reducing Surgeries for Hereditary Ovarian Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT01847274","title":"A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT01846611","title":"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":581,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT04111978","title":"MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Swiss GO Trial Group","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04022863","title":"Ovarium Cancer Detection by TEP's and ctDNA","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Gynaecologisch Oncologisch Centrum Zuid","has_results":false},{"nct_id":"NCT02354586","title":"A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":463,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT04971421","title":"Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT07286266","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02494037","title":"The Canadian/US Integrative Oncology Study","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"The Canadian College of Naturopathic Medicine","has_results":false},{"nct_id":"NCT02674061","title":"Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":376,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04593381","title":"Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":376,"lead_sponsor_name":"Gemelli Molise Hospital","has_results":false},{"nct_id":"NCT03012620","title":"Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":334,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT05242861","title":"Retrospective Study of Brachytherapy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05763511","title":"Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":292,"lead_sponsor_name":"Bicara Therapeutics","has_results":false},{"nct_id":"NCT04794322","title":"Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06242392","title":"The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT05194072","title":"A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":250,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT02903004","title":"Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT02632448","title":"A Study of LY2880070 in Participants With Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Esperas Pharma Inc.","has_results":false},{"nct_id":"NCT01905592","title":"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":216,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT04222465","title":"Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04351139","title":"Impact of the COVID-19 Pandemic in Gynecological Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT02785731","title":"Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.","phase":"","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Angle plc","has_results":false},{"nct_id":"NCT05610501","title":"Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT02781272","title":"Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Angle plc","has_results":false},{"nct_id":"NCT05734911","title":"Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study","phase":"","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"Zhongda Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}